ABCG1 as a potential oncogene in lung cancer

CHUNYAN TIAN\textsuperscript{1*}, DI HUANG\textsuperscript{2*}, YANLI YU\textsuperscript{1}, JIHONG ZHANG\textsuperscript{3}, QINGXIN FANG\textsuperscript{1} and CHAO XIE\textsuperscript{4}

\textsuperscript{1}Department of Health Care and Geriatrics, Yidu Central Hospital Affiliated to Weifang Medical University, Qingzhou, Shandong 262500; \textsuperscript{2}Department of Clinical Medicine, Medical School of Shandong University, Jinan, Shandong 250012; \textsuperscript{3}Department of Critical Care Medicine (ICU), Weifang People's Hospital, Weifang, Shandong 261041; \textsuperscript{4}The Third Department of Internal Medicine, Shandong Cancer Hospital, Jinan, Shandong 250017, P.R. China

Received September 18, 2015; Accepted November 18, 2016

DOI: 10.3892/etm.2017.4393

Abstract. ATP-binding cassette transporter G1 (ABCG1) is a member of the ABC transporter family and regulates cellular cholesterol homeostasis. It has important roles in cholesterol homeostasis and tumor immunity, which has, however, not been reported in lung cancer. The present study showed that ABCG1 protein is upregulated in lung cancer compared with adjacent normal tissues and furthermore, aberrant ABCG1 expression was detected in lung cancer cell lines. ABCG1 was shown to promote the proliferation of HKULC4 lung cancer cells. Moreover, ABCG1 was found to regulate proliferation-, apoptosis- and cancer stem cell-associated markers in HKULC4 cells, implying that ABCG1 has important roles not only in the regulation of proliferation but also of apoptosis and cancer stem cells. A microRNA microarray analysis showed that ABCG1 significantly downregulated miR-29a, -b and -c expression in HKULC4 cells. Finally, it was demonstrated that ABCG1 promoted the migration and invasion in HKULC4 cells. Thus, ABCG1 may be a novel therapeutic target to improve the treatment of non-small cell lung cancer.

Introduction

Lung cancer is the most common cause of cancer-associated mortality, with >226,000 new cases in the USA. Non-small cell lung cancer (NSCLC) is by far the most common type of lung cancer, accounting for ~80% of cases (1). In spite of marked improvements in radiotherapy and chemotherapy over the past few decades, the prognosis for patients with NSCLC is dismal, with the 5-year survival rate only being slightly above 15% (2). Thus, to improve the treatment of NSCLC, it is urgently required to identify novel markers as well as therapeutic targets and strategies.

ATP-binding cassette transporter G1 (ABCG1) is a member of the ABC transporter family and regulates cellular cholesterol homeostasis (3). Cholesterol homeostasis is crucial for the function and survival of cells (4). ABCG1 engages in reverse cholesterol transport by effluxing excess cholesterol from cells to high-density lipoprotein (HDL) particles, which is the only path for elimination of cholesterol from the body (5,6). Furthermore, ABCG1 is important for intracellular cholesterol transport (7,8). It is ubiquitously expressed in numerous cell types, including endothelial cells, lymphocytes and myeloid cells (3). ABCG1 has been reported to be a mediator of tumor immunity. ABCG1 deficiency in mice dramatically suppressed subcutaneous growth of B16-melanoma and MB49-bladder carcinoma cells and prolonged survival (9). However, to the best of our knowledge, the role of ABCG1 has, so far, not been reported in lung cancer.

MicroRNA (miRNA/miR) are endogenous short non-coding RNA molecules of 18-25 nucleotides in length that regulate gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner (10-12). Abnormal miRNA expression has been implicated in a multitude of cellular processes, including proliferation, apoptosis, migration and differentiation, and linked to various diseases, including cancer (12-18).

The present study showed that ABCG1 protein is upregulated in lung cancer compared with adjacent normal tissues and aberrant ABCG1 expression was detected in lung cancer cell lines. In HKULC4 lung cancer cells, ABCG1 promoted proliferation. Moreover, ABCG1 regulated proliferation-, apoptosis- and cancer stem cell-associated markers in HKULC4 cells, implying that it has important roles not only in the regulation of proliferation, but also of apoptosis and may also be of significance in cancer stem cells. By using a microRNA microarray, ABCG1 was found to significantly downregulate miR-29a, miR-29b and miR-29c expression in HKULC4 cells. Finally, the present study demonstrated that ABCG1 promoted migration and invasion of HKULC4 cells. Thus, ABCG1 is a novel potential therapeutic target to improve the treatment of NSCLC.

Materials and methods

Ethics statement. The present study was approved by the Medical Ethics Committee of the Medical School of Shandong
University (Jinan, China). All experiments were monitored and approved by the Yuncheng Second People's Hospital (Yuncheng, China). Written informed consent was provided by all patients enrolled in the present study.

Tissue samples. Lung cancer tissues and adjacent normal tissues were obtained from Shandong Cancer Hospital (Qingzhou, China) between January 2010 and January 2015. All tissues were examined histologically and pathologists confirmed the diagnosis. The medical ethics committee approved and monitored the experiments undertaken. The study also followed the internationally and locally accepted ethical guidelines of the Declaration of Helsinki, as well as the local laws.

Cell culture. The NCSLC cell lines H1650, HKULC2, H1299, HKULC4, HCC827 and H23 were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were maintained in RPMI medium supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Western blot analysis. Tissues and cells were dissolved in lysis buffer containing 1 mM phenylmethylsulfonyl fluoride (Beijing Solarbio Biological Technology Co., Ltd., Beijing, China). Protein concentration was determined using a bicinchoninic acid kit (Tiangen Biotech Co., Ltd., Beijing, China). Subsequently, 20 µg of total protein from the different samples was loaded per lane and subjected to 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% skimmed milk and incubated overnight at 4°C with primary antibodies, including rabbit anti-human monoclonal anti-ABCG1 (1:5,000; ab52617), anti-c-Myc (1:5,000; ab32072), anti-p21 (1:5,000; ab109520), anti-p53 (1:5,000; ab32049), anti-Ki-67 (1:5,000; ab15580), anti-retinoblastoma (1:5,000; ab47763), anti-B-cell lymphoma 2 (BCL2; 1:5,000; ab23124), anti-myeloid cell leukemia 1 (MCL1; 1:5,000; ab32087), anti-CD133 (1:5,000; ab32077) and anti-aldehyde dehydrogenase (ALDH; 1:5,000; ab52492; all Abcam, Cambridge, MA, USA). The membranes were washed with PBS containing 0.05% Tween-20 (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., Beijing, China) and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:10,000; ab6721; Abcam). The membrane was placed in an enhanced chemiluminescence solution (Tiangen Biotech Co., Ltd.) and exposed to a Gel Doc EZ Imager (Bio-Rad Laboratories, Inc., Hercules, USA). Image Lab v3.0 software (Bio-Rad Laboratories, Inc.) was used for protein band analysis. The relative content of the target protein was determined as the ratio to the internal reference β-actin.

MTT assay. The cell growth-inhibitory activity was assessed by an MTT assay. HKULC4 cells were seeded in a 96-well plate (2,000 cells/well) and exposed to fresh medium with ABCG1-expressing plasmids or empty vectors (pcDNA 3.1; both Tiangen Biotech Co., Ltd.) for 48 h. Subsequently, 20 µl MTT solution (5 mg/ml; Sigma-Aldrich; Merck-Millipore, Darmstadt, Germany) was added. Following incubation for 4 h at 37°C, the medium was discarded and the formed formazan crystals were dissolved in DMSO (150 µl/well). The absorbance, which is directly proportional to the number of viable cells, was measured at a wavelength of 490 nm using a multilabel counter microplate reader (Safire; Tecan Austria GmbH, Grödig, Austria).

Cell cycle analysis. Cells were seeded into a 6-well culture plate (1x10^5 cells/well) and transfected with plasmids for 24 h, washed twice with PBS and then centrifuged at 1,000 x g for 5 min at room temperature. The pellet was resuspended and fixed in 70% ethanol for at least 12 h at 4°C. The fixed cells were incubated with DNase-free RNaseA and propidium iodide (PI; Nanjing Kajji Biological Technology Development Co., Ltd., Nanjing, China) according to the manufacturer's instructions. The stained cells were analyzed using a flow cytometer (BD Accuri™ C6; BD Biosciences, Franklin Lakes, NJ, USA).

5-Bromo-2'-deoxyuriduride (BrdU) incorporation assay. BrdU incorporation reflects the rate of DNA synthesis. HKULC4 cells transfected with ABCG1-expressing plasmid or empty vector after 48 h were cultured in 96-well microplates (2,000 cells/well), followed by incubation with bromodeoxyuridine (BrdU; Roche Diagnostics, Indianapolis, IN, USA) for 4 h. After the culture supernatant was removed, the cells were fixed and incubated with anti-BrdU antibody (1:5,000; ab6326; Abcam) and detected and quantified using a flow cytometer (BD Accuri™ C6; BD Biosciences) (19).

miRNA detection. Total RNA from cultured cells, with efficient recovery of small RNA, were isolated using a mirVana™ miRNA Isolation kit (Ambion, Austin, TX, USA). cDNA for each sample was synthesized by using the 3' IVT Express kit (Affymetrix, Santa Clara, CA, USA) according to the supplier's protocol. The purified cDNA was fragmented by incubation in fragmentation buffer (provided in the 3'IVT Express kit) at 95°C for 35 min and chilled on ice. The fragmented labeled cDNA was subjected to an miRNA 2.0 array (Affymetrix) and hybridized in a Genechip hybridization oven 640 (Affymetrix) at 45°C for 18 h. After washing and staining in a GeneChip Fluidics Station 450 (Affymetrix), the arrays were scanned by using GeneChip Scanner 3000 (Affymetrix). The gene expression levels of samples were normalized and compared by using Partek Genomics Suite 6.5 (Partek Inc., St. Louis, MO, USA). Average-linkage hierarchical clustering of the data was applied by using the Cluster function and the results were displayed by using TreeView (http://genome-www.stanford.edu/clustering/).

In vitro migration and invasion assays. Transwell migration assays were performed in 24-well plates (BD Biosciences) with non-coated membrane, while invasion assays were performed with Matrigel-coated membrane (pore size, 8 mm; BD Biosciences). In each assay, 1x10^5 cells suspended in 200 µl serum-free RPMI-1640 medium that had been transfected with ABCG1-expressing plasmids or empty vectors were seeded into the upper chamber. A total of 500 µl RPMI-1640 medium supplemented with 10% FBS was added to the lower chamber. Following 24-h incubation, the cells on the upper side of the membrane were gently removed and the cells on the lower surface of the insert were stained with crystal violet and counted as described previously (20).
Results

**ABCG1 is upregulated in lung cancer tissues and aberrantly expressed among various lung cancer cell lines.** In an attempt to identify ABCG1 expression in lung cancer tissues and adjacent normal tissues, western blot analysis was performed. Protein was isolated from 8 pairs of lung cancer and adjacent normal tissues. ABCG1 protein was revealed to be significantly increased in cancer tissues compared with adjacent normal tissues (Fig. 1A). This implied that ABCG1 may be an oncogene in lung cancer. In order to identify the protein expression of ABCG1 among different lung cancer cell lines, western blot analysis of lysates of lung cancer cell lines (H1650, HKULC2, H1299, HKULC4, HCC827 and H23) was performed. ABCG1 expression was revealed to be lowest in HKULC4 cells (Fig. 1B).

**ABCA1 overexpression promotes proliferation of lung cancer HKULC4 cells.** To investigate whether ABCG1 promotes the proliferation of lung cancer cells, HKULC4 cells were transfected with ABCG1-expressing plasmid and stable overexpression of ABCG1 protein was assessed by western blot analysis. The results showed that ABCG1 was significantly increased by transfection with ABCG1-expressing plasmid (Fig. 2A). In order to determine the effect of ABCG1 on proliferation, an MTT assay was performed. The results showed that overexpression of ABCG1 significantly promoted the proliferation of HKULC4 cells (Fig. 2B). To further elucidate the effects of ABCG1 on proliferation, cell cycle analysis was performed. The results showed that HKULC4 cells transfected with ABCG1-expressing plasmid had higher S-phase fractions than those transfected with empty vector (Fig. 2C). To further confirm that promotion of DNA synthesis contributed to higher S-phase fractions in HKULC4 cells transfected with ABCG1-expressing plasmids, a BrdU incorporation assay was performed. The results confirmed that compared with the empty vector group, transfection with ABCG1-expressing vector significantly promoted DNA synthesis in the cells, as shown by increased BrdU incorporation in the representative micrographs and quantified bar graph (Fig. 2D).

**ABCG1 regulates proliferation-, apoptosis- and cancer stem cell-associated markers in HKULC4 lung cancer cells.** In a subsequent experiment, western blot analysis was employed to identify whether the protein levels of proliferative markers were affected by ABCG1 in the cells. The results of the western blot analysis showed that c-Myc expression was upregulated, while p21 and p53 expression were downregulated by ABCG1-expressing plasmids in the cells (Fig. 3). In addition, the levels of apoptosis markers were assessed, revealing that BCL2 and MCL1 were upregulated by ABCG1 in HKULC4 cells (Fig. 3). Furthermore, the cancer stem cell-associated markers CD133 and ALDH were found to be increased in HKULC4 cells with ABCG1 overexpression (Fig. 3).

**ABCG1 significantly downregulates miR-29a, miR-29b and miR-29c expression in lung cancer HKULC4 cells.** Oncogenes may exert their functions by regulating miRNA expression in lung cancer (21). A number of miRNA are involved in lung cancer pathogenesis, which may either function as tumor suppressor genes or oncogenes (22). Thus, it was reasoned that ABCG1 may function as an oncogene by regulating relevant miRNA. An miRNA microarray analysis was performed by isolating RNA from HKULC4 cells transfected with ABCG1 expression or empty vector and hybridizing them to a custom miRNA microarray platform. After three repetitions of hybridization, quantification and normalization, miR-29a, -b and -c were found to be downregulated by >100-fold in the cells (Fig. 4).

**ABCG1 promotes migration and invasion in HKULC4 lung cancer cells.** To determine whether ABCG1 overexpression increases the basal levels of cell migration or invasion, HKULC4 cells were subjected to Transwell assays. Ectopic expression of ABCG1 resulted in a 4-fold increase in cell invasion and a 5.5-fold increase in cell migration (Fig. 5). These results indicated that overexpression of ABCG1 promoted migration and invasion in HKULC4 lung cancer cells.

Discussion

The present study identified a novel role for the cholesterol transporter ABCG1 as a modulator of proliferation, migration, invasion, apoptosis and microRNA regulation in lung cancer. This result is consistent with a previous study reporting that the absence of ABCG1 inhibits tumor growth through the modulation of macrophage survival and phenotype within the tumor (9). The present study found that ABCG1 overexpression not only promoted proliferation, but also upregulated the expression of the anti-apoptotic proteins BCL2 and MCL1 in HKULC4 lung cancer cells. ABCG1 effluxes excess cholesterol from cells to HDL particles for reverse cholesterol transport, which is the only pathway for cholesterol elimination from the body (5,6). Studies have demonstrated that pulmonary macrophages of...
ABCGL-/- mice accumulate massive levels of cholesterol and sterol esters, consistent with these cells being particularly sensitive to loss of function of this transporter (5,23-25). These lipid-loaded ABCGL-/-pulmonary macrophages also undergo increased apoptosis (26). It is probable that the accumulation of cholesterol that produced specific toxic effects induced apoptosis in lung cancer cells.

Lung cancer contains a rare population of CD133+ cancer stem-like cells with the ability to self-renew, which generates an unlimited progeny of non-tumorigenic cells (27). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are resistant to cisplatin treatment (28). Increased ALDH1 activity has been found in stem cell populations in human brain and breast cancer, acute myeloid leukemia...
and multiple myeloma (29-36). Therefore, ALDH1 activity may be utilized as a common marker for normal as well as malignant stem cell populations (36). ALDH1 expression has been reported in certain lung cancer cell lines (37), and the increased expression of ALDH1 could result from cigarette smoking and contribute to malignant transformation of lung cells (38). ALDH1 has been suggested to be a tumor stem cell-associated marker in lung cancer (39). The results of the present study showed that ABCG1 upregulated CD133 and ALDH1 expression in lung cancer, implying that ABCG1 is a regulator of lung cancer stem cells.

It has been reported that in lung cancer, expression profiles of miRNA are different from those in normal lungs; however, the significance of this aberrant expression remains poorly understood. Among the miRNA reported to be downregulated in lung cancer, the miR-29 family (miR-29a, -b and -c) target the 3'-untranslated region and downregulate the expression of DNA methyltransferase (DNMT) 3a and -b, two key enzymes involved in DNA methylation, which are frequently upregulated in lung cancer and associated with poor prognosis (22,40). The
present study showed that ABCG1 overexpression significantly inhibited miR-29a,-b and -c expression. A future study will determine whether ABCG1 affects DNMT 3a and -b.

References

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Pastirno U: Lung cancer screening. Br J Cancer 102: 1681-1686, 2010.
3. Tarr PT, Tarling EJ, Bojanic DD, Edwards PA and Baldán A: Emerging new paradigms for ABCG transporters. Biochem Soc Trans 37: 893-909, 2009.
4. Ikonen E: Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9: 125-138, 2008.
5. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, Frank J, Francone OL and Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1: 121-131, 2005.
6. Wang N, Lan D, Chen W, Matsuura F and Tall AR: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101: 9774-9779, 2004.
7. Sturek JM, Cie J, Trace AP, Page LC, Castle AM, Evans-Molina C, Parks JS, Mirrira RG and Hedrick CC: An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J Clin Invest 120: 2575-2589, 2010.
8. Tarling EJ, Edwards PA: ATP-binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc Natl Acad Sci USA 108: 19719-19724, 2011.
9. Sag D, Cekic C, Wu R, Linden J and Hedrick CC: The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nature 525: 635-638, 2015.
10. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic regulatory RNA lin-14. Cell 75: 843-854, 1993.
11. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, et al: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89, 2000.
12. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettiger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
13. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
14. Meng F, Henson R, Welm-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
15. Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene 25: 6176-6187, 2006.
16. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
17. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 239-249, 2006.
18. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 555-567, 2006.
19. Liu SH, Yang RS, Yen YP, Chiu CY, Tsai KS and Lan KC: Low-concentration arsenic trioxide inhibits skeletal myoblast cell proliferation via a reactive oxygen species-independent pathway. PLoS One 10: e0137907, 2015.
20. Xie B, Lin W, Ye J, Wang X, Zhang B, Xiong S, Li H and Tan G: DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAI1. J Clin Clin Cancer Res 34: 101, 2015.
21. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106: 12085-12090, 2009.
22. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
23. Out R, Hoekstra M, Hildebrand RB, Kruit JK, Meurs I, Li Z, Kuipers F, Van Berkel TJ and Van Eck M: Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 26: 2295-2300, 2006.
24. Baldán A, Gomes AV, Ping P and Edwards PA: Loss of ABCG1 results in chronic pulmonary inflammation. J Immunol 180: 3560-3568, 2008.
25. Baldán A, Tarr P, Vales CS, Frank J, Shimotake TK, Hawgood S and Edwards PA: Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis. J Biol Chem 281: 29401-29410, 2006.
26. Wojcik AJ, Skafien MD, Srinivasan S and Hedrick CC: A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol 180: 4273-4282, 2008.
27. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Dis 15: 504-514, 2008.
28. Bertolini G, Roz L, Peregó P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbrì A, Andritani F, Tinelli S, et al: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 26511-26516, 2009.
29. Armstrong L, Stojkovic M, Dimick I, Ahmad S, Stojkovic P, Hole N and Lako M: Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22: 1142-1151, 2004.
30. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ and McDonnell DP: Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 26: 611-620, 2008.
31. Hess DA, Wirthlin L, Craft TP, Herrlich PE, Hohm SA, Lahey R, Eades WC, Creer MH and Nolta JA: Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107: 2162-2169, 2006.
32. Pearce DJ, Tausig D, Simpson C, Allen K, Rohatiner AZ, Lister TA and Bonnet D: Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 6: 752-760, 2005.
33. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquierm J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 15: 555-567, 2009.
34. Feldmann G, Dharra S, Fendrich V, Bedja D, Beatty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, et al: Blockade of hedgehog signaling inhibits pancreatic cancer cell invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 67: 2187-2196, 2007.
35. Balicki D: Moving forward in human mammary stem cell biology and breast cancer prognosis using ALDH1. Cell Stem Cell 15: 485-487, 2014.
36. Sreerama L and Sladek NE: Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the national cancer institute to screen for potentially useful antitumor agents. Adv Exp Med Biol 414: 81-94, 1997.
37. Patel M, Lai L, Zander DS, Sreerama L, Coco D and Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers: Correlation with histologic type and potential precursors. Lung Cancer 59: 340-349, 2008.
38. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Y, Su Y, Stass SA and Katz RL: Aldehyde dehydrogenase 1a in a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338, 2009.
39. Volinia S, Calin GA, Liu CG, Ambros V, Petrocca F, Visonne R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.